Autolus Therapeutics (NASDAQ:AUTL) plc, a biopharmaceutical company, announced the results of its Annual General Meeting (AGM) held today, with shareholders passing all nine resolutions on the agenda. The voting outcomes, detailed in the company's 8-K filing with the Securities and Exchange Commission, included the adoption of the company's 2023 financial statements and the re-election of several directors.
The first resolution, which involved the reception and adoption of the company's accounts for the year ended December 31, 2023, along with reports from directors and auditors, passed with overwhelming support, garnering 190,777,881 votes in favor.
Shareholders also approved the Directors' remuneration report, with 167,097,615 votes cast in support. Ernst & Young LLP was re-appointed as the company's auditors, with 190,779,304 votes for the resolution.
In the directorial re-elections, Ms. L Bain, Ms. C Butitta, Dr. C Itin, and Dr. W Young were all successfully re-elected to the board, with each receiving significant majority support.
Further, the shareholders authorized the board to allot shares and grant rights up to a specified nominal amount, as well as to allot equity securities for cash as if certain statutory pre-emption rights did not apply. These resolutions, concerning the company's share capital management, passed with 162,362,965 and 157,588,468 votes for, respectively.
The results reflect confidence in the current management and strategic direction of Autolus Therapeutics, which specializes in the development of next-generation, programmed T cell therapies for the treatment of cancer.
The company, incorporated in England and Wales with headquarters in London, is known for its focus on innovative biotechnological products. Trading on the Nasdaq Global Select Market under the ticker NASDAQ:AUTL, Autolus Therapeutics continues to be a key player in the biopharmaceutical industry.
The AGM's outcomes, as per the Proxy Statement filed on June 5, 2024, are expected to support Autolus in its ongoing and future endeavors. This report is based solely on the information provided in the company's SEC filing.
In other recent news, Autolus Therapeutics has reported encouraging data from its FELIX study on the treatment of adult B-cell Acute Lymphoblastic Leukemia (ALL) with obecabtagene autoleucel (obe-cel). The study showed that 40% of patients who responded to obe-cel are in ongoing remission without the need for subsequent stem cell transplant or other therapy. The results of the FELIX trial have been submitted to the FDA, with a target action date set for November 16, 2024.
In related news, Truist Securities maintained a Buy rating on shares of Autolus Therapeutics with minor revisions to the projected market penetration for Obe-cel. Wells Fargo reiterated its Overweight rating on Autolus Therapeutics stock based on anticipated positive developments in the second half of 2024, including a PDUFA decision for B-ALL treatment.
In financial updates, Autolus Therapeutics reported a net loss per share of $0.24 in its first-quarter 2024 earnings, which was wider than the consensus estimate of a $0.08 loss per share. However, the company had $758.5 million in cash and equivalents at the end of the quarter. Autolus is well-capitalized to support the full launch of obe-cel for relapsed/refractory adult acute lymphoblastic leukemia (ALL) and to progress its pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.